DETECT III – a multicenter, randomized, phase III study to compare standard therapy alone versus standard therapy plus lapatinib in patients with initially HER2-negative metastatic breast cancer and HER2-positive circulating tumor cells - Melcher, C A; Janni, W; Rack, B (Eur J Cancer, 2012)
et al.